{"entity":{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","aka":[],"tldr":"Later report from the trial registered as NCT04395677, in Journal of Clinical Oncology (2026); its title describes an updated or longer-term analysis.","summary":"Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) with activity against the ROS1 G2032R resistance mutation. Initial data from the TRUST-I study (ClinicalTrials.gov identifier: NCT04395677) demonstrated high response rates and intracranial (IC) activity, with promising durability, in Chinese patients with advanced ROS1 + non-small cell lung cancer (NSCLC). With longer follow-up, taletrectinib continued to demonstrate high and durable response rates in both TKI-naïve and crizotinib-pretreated patients, including IC activity and promising overall survival (OS). Among 103 TKI-naïve patients who started taletrectinib at 600 mg once daily (median follow-up, 51.0 months), the objective response rate (ORR) was 90.3% (95% CI, 82.9 to 95.3), the median duration of response (DOR) and median progression-free survival (PFS) exceeded 4 years (49.7 months and 49.6 months, respectively), and median OS was not reached. Among 66 crizotinib-pretreated patients (median follow-up, 45.2 months), the ORR was 51.5%, the median DOR was 13.2 months, the median PFS was 7.6 months, and the median OS was 25.6 months. The safety profile remained consistent with prior reports, and no new safety signals were identified. Overall, taletrectinib demonstrated durable long-term efficacy and a manageable safety profile in patients with advanced ROS1 + NSCLC.\n\nIndexed on Europe PMC as PubMed record 42013573 (DOI 10.1200/jco-26-00434). Its abstract cites the registry id NCT04395677, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"J Clin Oncol 2026","url":"https://doi.org/10.1200/jco-26-00434"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42013573/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/42013573"},{"label":"ClinicalTrials.gov NCT04395677","url":"https://clinicaltrials.gov/study/NCT04395677"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04395677"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2026,"doi":"10.1200/jco-26-00434","pmid":"42013573","authors":"Li W, Zhang Y, Fan H, et al.","paperType":"observational","findings":[],"whatItMeans":"A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","Chosen as a later report by words in its title (updated, long-term, final, overall survival or a year count), not by reading the paper."]},"route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/","neighbours":{"trial":[{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","route":"/trials/nct04395677/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}